CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Pfizer, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.
ReMediES Legacy Training
CMAC was a partner in ReMediES. An output of the project is this training package now online..... more
Check out latest CMAC vancancies
Check our latest vacancies.... more
Winner of BACG Crystal in Art
CMAC PhD researcher Hector Polyzois has won with his image 'Twisting of Pharmaceutical Crystals'..... more